These results indicate that miR-29a/b/c inhibit G1/S-phase transition and glioma cell proliferation by direct targeting of the TRAF4/AKT/GSK-3β pathway and the suppression of c-Myc and cyclin D1 expression (Fig. 8c). This evidence concerns the gene CCND1 and central nervous system cancer.